The companies are seeking the FDA's approval for use of the therapy in infants and children up to 24 months of age to protect them against lower respiratory tract disease that could cause pneumonia and bronchiolitis.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/cdt98uV
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Sanofi and AstraZeneca's preventive RSV therapy appears safe: FDA staff
https://ift.tt/Wm7b4L9
No comments:
Post a Comment